Intelligent Bio Solutions Inc. announced that it is entering the next phase of its planned 510(k) submission to the FDA. The company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and sampling study subjects today. INBS' PK study is a key step towards the Company's planned 510(k) submitted to the FDA during the fourth quarter of this year.

FDA clearance is required to show that INBS' fingerprint drug screening technology is safe and effective and would result in the Company's ability to enter the substantial US market, currently planned for the first half of 2025. INBS aims to complete the dosing and sampling of the recruited subjects by the end of June 2024, with a review of the PK study results expected to be finalized by the end of July 2024. The PK study will provide insights into the metabolism, distribution, and excretion of opiates, with a specific focus on human sweat.

The study will gather and analyze fingerprint sweat samples and compare the results with blood, saliva, and urine samples.